Danilo Corazza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danilo Corazza has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Karla dos Santos Borges
Laboratory of Cellular Immunology, Pathology Area, Faculty of Medicine, University of Brasilia, Brasilia, Brazil
2 shared publications - Ana Carolina Laraia Ciarlini
University of Brasília, Faculty of Medicine, Laboratory of Cellular Immunology, Campus Darcy Ribeiro, Brasilia, Distrito Federal 70910-900, Brazil
1 shared publication - Andreia Cristina Gonçalves Cascaes Gontijo
University of Brasília, Faculty of Medicine, Laboratory of Cellular Immunology, Campus Darcy Ribeiro, Brasilia, Distrito Federal 70910-900, Brazil
1 shared publication - Andressa Souza de Oliveira
University of Brasília, Faculty of Health Sciences, Department of Pharmacy, Campus Darcy Ribeiro, Brasilia, Distrito Federal, 70910-900, Brazil
1 shared publication - Ciro Martins Gomes
Universidade de Brasília, Brasil
1 shared publication - Jorgeth de Oliveira Carneiro da Motta
Department of Dermatology, Hospital Universitário de Brasília, Brasilia, DF, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e03362021
Dramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways
A 39-year-old woman was diagnosed with relapsed multibacillary leprosy and refractory neuritis. Here, we describe an evident loss of therapeutic effectiveness after the third pulse of corticosteroids, which may be attributed to tachyphylaxis and the posterior modulation of interferon- γ (IFN-γ), tumor necrosis factor- α (TNF-α,) interleukin-17A (IL-17A), and IL-12/23p40 after the induction phase of secukinumab. In this case, plasma cytokine analysis showed that secukinumab induced a reduction in IL-17 concomitant with impressive clinical improvements in the patient’s neural function. Interestingly, secukinumab induced reductions in cytokines related to Th1 responses and earlier stages of the Th17 response, including IL-23/12.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e03362021
Open AccessDramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways
A 39-year-old woman was diagnosed with relapsed multibacillary leprosy and refractory neuritis. Here, we describe an evident loss of therapeutic effectiveness after the third pulse of corticosteroids, which may be attributed to tachyphylaxis and the posterior modulation of interferon- γ (IFN-γ), tumor necrosis factor- α (TNF-α,) interleukin-17A (IL-17A), and IL-12/23p40 after the induction phase of secukinumab. In this case, plasma cytokine analysis showed that secukinumab induced a reduction in IL-17 concomitant with impressive clinical improvements in the patient’s neural function. Interestingly, secukinumab induced reductions in cytokines related to Th1 responses and earlier stages of the Th17 response, including IL-23/12.